{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:46:33Z","timestamp":1791942393799,"version":"4.3.4"},"reference-count":600,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["S10OD030286"],"award-info":[{"award-number":["S10OD030286"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL146691"],"award-info":[{"award-number":["R01-HL146691"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32-HL144456"],"award-info":[{"award-number":["T32-HL144456"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL159062"],"award-info":[{"award-number":["R01-HL159062"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL164772"],"award-info":[{"award-number":["R01-HL164772"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK033823"],"award-info":[{"award-number":["R01-DK033823"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK123259"],"award-info":[{"award-number":["R01-DK123259"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007878","name":"Diabetes Research Center","doi-asserted-by":"publisher","award":["R01-HL138720"],"award-info":[{"award-number":["R01-HL138720"]}],"id":[{"id":"10.13039\/100007878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007878","name":"Diabetes Research Center","doi-asserted-by":"publisher","award":["R01-HL091469"],"award-info":[{"award-number":["R01-HL091469"]}],"id":[{"id":"10.13039\/100007878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007878","name":"Diabetes Research Center","doi-asserted-by":"publisher","award":["R01-HL179656"],"award-info":[{"award-number":["R01-HL179656"]}],"id":[{"id":"10.13039\/100007878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000965","name":"American Federation for Aging Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1-TR004400"],"award-info":[{"award-number":["UM1-TR004400"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1-TR002556-06"],"award-info":[{"award-number":["UL1-TR002556-06"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032645","name":"Hevolution Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["AHA-POST836407"],"award-info":[{"award-number":["AHA-POST836407"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["AHA-POST1195524"],"award-info":[{"award-number":["AHA-POST1195524"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["AHA-POST35211151"],"award-info":[{"award-number":["AHA-POST35211151"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["AHA-POST915561"],"award-info":[{"award-number":["AHA-POST915561"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["T32-HL-172255"],"award-info":[{"award-number":["T32-HL-172255"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pcad.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:04:42Z","timestamp":1755648282000},"page":"43-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Fabry disease cardiomyopathy: A state-of-the-art review"],"prefix":"10.1016","volume":"92","author":[{"given":"Shivangi","family":"Pande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Varzideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislovas S.","family":"Jankauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Andrea","family":"Cerasuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urna","family":"Kansakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin J.","family":"Kurland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Sidoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sadoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Santulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2025.08.003_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of \u201cAngeio-Keratoma\u201d","volume":"10","author":"Anderson","year":"1898","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","article-title":"Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)","volume":"43","author":"Fabry","year":"1898","journal-title":"Arch Dermatol Syph"},{"key":"10.1016\/j.pcad.2025.08.003_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.813637","article-title":"Role of Globotriaosylceramide in Physiology and Pathology","volume":"9","author":"Celi","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0025","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pcad.2025.08.003_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40246-024-00697-3","article-title":"Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease","volume":"18","author":"Yao","year":"2024","journal-title":"Hum Genomics"},{"key":"10.1016\/j.pcad.2025.08.003_bb0035","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/ehjci\/jeae224","article-title":"CMR to characterize myocardial structure and function in heart failure with preserved left ventricular ejection fraction","volume":"25","author":"Ipek","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J Genet Couns"},{"key":"10.1016\/j.pcad.2025.08.003_bb0045","doi-asserted-by":"crossref","DOI":"10.2196\/55001","article-title":"Medical expert knowledge meets AI to enhance symptom checker performance for rare disease identification in Fabry disease: mixed methods study","volume":"4","author":"Pankow","year":"2025","journal-title":"JMIR AI."},{"key":"10.1016\/j.pcad.2025.08.003_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jjcc.2013.02.012","article-title":"Japanese Patients With Fabry disease Predominantly Showing Cardiac and Neurological Manifestation With Novel Missense Mutation: R220P","volume":"62","author":"Fukutomi","year":"2013","journal-title":"J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/ehjqcco\/qcaf093","article-title":"Cardiopulmonary exercise test and stress echocardiography in Fabry cardiomyopathy: insights into functional impairment and risk stratification","author":"Mistrulli","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.pcad.2025.08.003_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.32756\/0869-5490-2021-4-6-12","article-title":"Family Genetic Screening in Rare Hereditary Diseases","volume":"31","author":"Kutsev","year":"2021","journal-title":"Clinical Pharmacology and Therapy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0065","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0070","first-page":"3","article-title":"Investigating Fabry disease - Some Lessons Learned","author":"Schiffmann","year":"2024","journal-title":"Rare Disease and Orphan Drugs Journal"},{"key":"10.1016\/j.pcad.2025.08.003_bb0075","series-title":"The Prevalence of Fabry disease in a Statewide Chronic Kidney Disease Cohort \u2013 Outcomes of the aCQuiRE (Ckd.Qld fabRy Epidemiology) Study","author":"Mallett","year":"2022"},{"key":"10.1016\/j.pcad.2025.08.003_bb0080","doi-asserted-by":"crossref","DOI":"10.4081\/cardiogenetics.2013.s1.e1","article-title":"Diagnosis and Management of Lysosomal Storage Disorders. Three Key Words: Early, Multidisciplinary, and Network","volume":"3","author":"Andria","year":"2013","journal-title":"Cardiogenetics"},{"key":"10.1016\/j.pcad.2025.08.003_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/2326409816666298","article-title":"A 15-Year Perspective of the Fabry Outcome Survey","volume":"4","author":"Giugliani","year":"2016","journal-title":"Journal of Inborn Errors of Metabolism and Screening"},{"key":"10.1016\/j.pcad.2025.08.003_bb0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000495886","article-title":"The Prevalence and Clinical Features of Fabry disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program","volume":"141","author":"Moiseev","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.pcad.2025.08.003_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0100","first-page":"11","article-title":"Newborn Screening for Fabry disease in Northeastern Italy: Results of Five Years of Experience","author":"Gragnaniello","year":"2021","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.pcad.2025.08.003_bb0105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/ehjqcco\/qcae052","article-title":"The Italian Fabry disease Cardiovascular Registry (IFDCR)","volume":"10","author":"Limongelli","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.pcad.2025.08.003_bb0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pcad.2025.08.003_bb0115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10157-015-1146-7","article-title":"Prevalence of Fabry disease in Dialysis Patients: Japan Fabry disease Screening Study (J-Fast)","volume":"20","author":"Sait\u00f4","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0120","article-title":"Prevalence of Fabry disease in Korean Men With Left Ventricular Hypertrophy","volume":"34","author":"Kim","year":"2019","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0125","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.3390\/jcm11247396","article-title":"Association of Fabry disease With Hearing Loss, Tinnitus, and Sudden Hearing Loss: A Nationwide Population-Based Study","volume":"11","author":"Cheng","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0130","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/genes11091091","article-title":"Biomarkers of Fabry Nephropathy: Review and Future Perspective","volume":"11","author":"Levstek","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.pcad.2025.08.003_bb0135","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0140","doi-asserted-by":"crossref","first-page":"1529267","DOI":"10.3389\/fneur.2025.1529267","article-title":"Cryptogenic strokes and neurological symptoms of Fabry disease","volume":"16","author":"Ruiz-Franco","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0145","doi-asserted-by":"crossref","unstructured":"Gragnaniello V, Burlina AP, Commone A, Gueraldi D, Puma A, Porcu E, Stornaiuolo M, Cazzorla C and Burlina AB. Newborn Screening for Fabry disease: Current Status of Knowledge. Int J Neonatal Screen. 2023;9.","DOI":"10.3390\/ijns9020031"},{"key":"10.1016\/j.pcad.2025.08.003_bb0150","doi-asserted-by":"crossref","first-page":"c33","DOI":"10.1159\/000085709","article-title":"Fabry disease in Patients With End-Stage Renal Failure: The Potential Benefits of Screening","volume":"101","author":"Bekri","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.pcad.2025.08.003_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244279","article-title":"The Patient Journey of Patients With Fabry disease, Gaucher Disease and Mucopolysaccharidosis Type II: A German-Wide Telephone Survey","volume":"15","author":"Mengel","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000448740","article-title":"Targeted Screening of Fabry disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening","volume":"134","author":"Silva","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.pcad.2025.08.003_bb0165","first-page":"1","article-title":"Anaesthesiologic Protocol for Kidney Transplantation in Two Patients With Fabry disease: A Case Series","author":"Sorbello","year":"2008","journal-title":"Cases J"},{"key":"10.1016\/j.pcad.2025.08.003_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-099735","article-title":"High prevalence of diabetes mellitus among patients with Fabry disease in Taiwan: a cross-sectional study","volume":"15","author":"Hung","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.pcad.2025.08.003_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/diseases12050102","article-title":"The Effect of Fabry disease Therapy on Bone Mineral Density","volume":"12","author":"Aitken","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.pcad.2025.08.003_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-02150-3","article-title":"A New Approach to Identifying Patients With Elevated Risk for Fabry disease Using a Machine Learning Algorithm","volume":"16","author":"Jefferies","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000493469","article-title":"Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry disease","volume":"141","author":"Riccio","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.pcad.2025.08.003_bb0190","first-page":"13","article-title":"Epidemiological and Clinical Profile of Patients With Fabry disease","author":"Aquino","year":"2019","journal-title":"Revista De Enfermagem Ufpe on Line"},{"key":"10.1016\/j.pcad.2025.08.003_bb0195","doi-asserted-by":"crossref","first-page":"394","DOI":"10.20517\/jtgg.2024.38","article-title":"The Underdiagnosed Kidney Burden of Fabry disease in Females","volume":"8","author":"Chandramohan","year":"2024","journal-title":"Journal of Translational Genetics and Genomics"},{"key":"10.1016\/j.pcad.2025.08.003_bb0200","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/1346-8138.17690","article-title":"Cutaneous manifestations of Fabry disease: A systematic review","volume":"52","author":"Al-Chaer","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0205","doi-asserted-by":"crossref","unstructured":"De Angelis G, Tsoumani Z, Reid A, Nucifora G, Irwin RB and Schmitt M. Late-Onset Fabry disease Presenting With Ventricular Tachycardia Originating From Typical Inferolateral Scar. Can J Cardiol 2020;36:1832 e1-1832 e4.","DOI":"10.1016\/j.cjca.2020.04.042"},{"key":"10.1016\/j.pcad.2025.08.003_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009709","article-title":"Severe Late-Onset Fabry Cardiomyopathy Unmasked by a Multimodality Imaging Approach","volume":"12","author":"Visoiu","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb0215","first-page":"19","article-title":"Late onset variants in Fabry disease: Results in high risk population screenings in Argentina","volume":"4","author":"Serebrinsky","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb0220","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1399-0004.1991.tb03018.x","article-title":"Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A","volume":"39","author":"Nagao","year":"1991","journal-title":"Clin Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0225","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","article-title":"Newborn Screening for Fabry disease in the North-West of Spain","volume":"176","author":"Col\u00f3n","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.pcad.2025.08.003_bb0230","first-page":"139","article-title":"Screening for Fabry disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation","volume":"105","author":"Baptista","year":"2015","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0235","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10545-012-9547-1","article-title":"Lyso-globotriaosylsphingosine (Lyso-Gb<sub>3<\/Sub>) Levels in Neonates and Adults With the Fabry disease Later-onset <i>GLA<\/I> IVS4+919G>A Mutation","volume":"36","author":"Chien","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0240","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymgmr.2018.07.001","article-title":"Fabry disease. A Potential Pitfall a Family With a Novel Intronic Mutation","volume":"17","author":"Gustavo","year":"2018","journal-title":"Molecular Genetics and Metabolism Reports"},{"key":"10.1016\/j.pcad.2025.08.003_bb0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/ijms18010119","article-title":"Correlations Between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients With the Chinese Hotspot IVS4+919G>A Mutation: Data From the Fabry Outcome Survey","volume":"18","author":"Hsu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0250","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-9-96","article-title":"Endomyocardial Biopsies in Patients With Left Ventricular Hypertrophy and a Common Chinese Later-Onset Fabry Mutation (IVS4+919G> A)","volume":"9","author":"Hsu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0255","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/cells13050437","article-title":"GLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry disease","volume":"13","author":"Li","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0260","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/8904_2015_418","article-title":"Age at First Cardiac Symptoms in Fabry disease: Association With a Chinese Hotspot Fabry Mutation (IVS4+919G>A), Classical Fabry Mutations, and Sex in a Taiwanese Population From the Fabry Outcome Survey (FOS)","author":"Liu","year":"2015","journal-title":"Jimd Reports"},{"key":"10.1016\/j.pcad.2025.08.003_bb0265","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2169\/internalmedicine.8213-21","article-title":"The 30-Year Natural History of Non-Classic Fabry disease With an R112H Mutation","volume":"61","author":"Muto","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0270","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene Mutations Versus Clinically Relevant Phenotypes","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0275","doi-asserted-by":"crossref","first-page":"315","DOI":"10.12659\/AJCR.897024","article-title":"p.R301X Mutation and Variable Phenotypic Appearance of Fabry disease","volume":"17","author":"\u00d6zelsancak","year":"2016","journal-title":"American Journal of Case Reports"},{"key":"10.1016\/j.pcad.2025.08.003_bb0280","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ana.26575","article-title":"Prevalence of Mutations in Mendelian Stroke Genes in Early Onset Stroke Patients","volume":"93","author":"Park","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0285","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/8904_2018_146","article-title":"Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant","author":"Talbot","year":"2018","journal-title":"Jimd Reports"},{"key":"10.1016\/j.pcad.2025.08.003_bb0290","first-page":"11","article-title":"Late-Onset Renal Variant Fabry disease With R112H Mutation and Mild Increase in Plasma Globotriaosylsphingosine: A Case Report","author":"Tanaka","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/8904_2012_167","article-title":"Questioning the Pathogenic Role of the GLA p.Ala143Thr \u201cMutation\u201d in Fabry disease: Implications for Screening Studies and ERT","author":"Terryn","year":"2012","journal-title":"Jimd Reports"},{"key":"10.1016\/j.pcad.2025.08.003_bb0300","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2169\/internalmedicine.52.9213","article-title":"A Mutant mRNA Expression in an Endomyocardial Biopsy Sample Obtained From a Patient With a Cardiac Variant of Fabry disease Caused by a Novel Acceptor Splice Site Mutation in the Invariant AG of Intron 5 of the \u0391-Galactosidase a Gene","volume":"52","author":"Watanabe","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0305","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/ehf2.15099","article-title":"Heart Failure in Two Male Patients With Late-onset Fabry Mutation (IVS4 + 919G > A)","volume":"12","author":"Yang","year":"2024","journal-title":"Esc Heart Failure"},{"key":"10.1016\/j.pcad.2025.08.003_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131295","article-title":"Clinical manifestation of patients with Fabry disease and R356W GLA variant","volume":"392","author":"Monda","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235687","article-title":"Cloning and Expression of a Novel \u0391-Galactosidase From Lactobacillus Amylolyticus L6 With Hydrolytic and Transgalactosyl Properties","volume":"15","author":"Fei","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2369-15-157","article-title":"A Rare Association Between Fabry\u2019s Disease and Granulomatosis With Polyangiitis: A Potential Pathogenic Link","volume":"15","author":"Hanaoka","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0325","doi-asserted-by":"crossref","first-page":"1651117","DOI":"10.3389\/fcvm.2025.1651117","article-title":"Editorial: Target organ damage in Fabry disease","volume":"12","author":"Iaccarino","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0330","article-title":"Expanded View of the Pathophysiology of Fabry disease","volume":"1-7","author":"Kmoch","year":"2025","journal-title":"Nephron"},{"key":"10.1016\/j.pcad.2025.08.003_bb0335","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2018.10.007","article-title":"Dissociation of Globotriaosylceramide and Impaired Endothelial Function in \u0391-Galactosidase-a Deficient EA.hy926 Cells","volume":"125","author":"Kaissarian","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0340","first-page":"69","article-title":"Fabry disease and Vascular Risk Factors: Future Strategies for Patient-based Studies and the Knockout Murine Model","volume":"95","author":"Moore","year":"2006","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.pcad.2025.08.003_bb0345","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, Phenotype and Disease Severity Reflected by Serum LysoGb3 Levels in Patients With Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0350","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","article-title":"Cellular and Tissue Distribution of Intravenously Administered Agalsidase Alfa","volume":"90","author":"Murray","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031331","article-title":"The Cardiovascular Phenotype in Fabry disease: New Findings in the Research Field","volume":"22","author":"Sorriento","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0360","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/eurheartjsupp\/suae104","article-title":"Cardiac involvement in Fabry disease: Recent advances, unresolved issues, and unmet needs","volume":"27","author":"Pieroni","year":"2025","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.pcad.2025.08.003_bb0365","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cjco.2025.01.017","article-title":"Utilization of Transthoracic Echocardiography and Biochemical Markers in Detecting Cardiomyopathy in Fabry disease","volume":"7","author":"Roy","year":"2025","journal-title":"CJC Open"},{"key":"10.1016\/j.pcad.2025.08.003_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/genes16050601","article-title":"Transcriptomic Approach in Understanding Fabry Nephropathy: A Review of the Literature and Proof-of-Concept","volume":"16","author":"Breznik","year":"2025","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb0375","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12882-025-04189-x","article-title":"The relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease","volume":"26","author":"Ozcan","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0380","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40620-024-01908-9","article-title":"Pathogenic pathways of renal damage in Fabry nephropathy: interplay between immune cell infiltration, apoptosis and fibrosis","volume":"37","author":"Bondar","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0385","doi-asserted-by":"crossref","first-page":"208","DOI":"10.23876\/j.krcp.20.264","article-title":"Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis","volume":"40","author":"Chung","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.pcad.2025.08.003_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063506","article-title":"Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease","volume":"8","author":"Liebau","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108565","article-title":"Assessment of combined alpha-GAL enzyme activity and lyso-GL3 for Fabry disease screening in women with chronic kidney disease","volume":"143","author":"Silva","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.117851","article-title":"Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients","volume":"556","author":"Ouyang","year":"2024","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb0405","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40620-023-01853-z","article-title":"Outcomes and management of kidney transplant recipients with Fabry disease: a review","volume":"37","author":"Yu","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0410","doi-asserted-by":"crossref","first-page":"71","DOI":"10.23876\/j.krcp.22.087","article-title":"Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea","volume":"43","author":"Cho","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.pcad.2025.08.003_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23876\/j.krcp.23.125","article-title":"Screening and diagnosis of Fabry disease in chronic kidney disease: the important role of globotriaosylsphingosine","volume":"43","author":"Shin","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.pcad.2025.08.003_bb0420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00467-023-06050-5","article-title":"Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease","volume":"39","author":"Avarappattu","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0425","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12882-025-04127-x","article-title":"Fabry disease in the haemodialysis population: outcome of a UK screening study (SoFAH)","volume":"26","author":"Ng","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0430","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-025-02312-7","article-title":"Screening for Fabry disease in patients on kidney replacement therapy at Padua University Hospital Nephrology Unit","author":"Carraro","year":"2025","journal-title":"J Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0435","doi-asserted-by":"crossref","first-page":"508","DOI":"10.23876\/j.krcp.21.235","article-title":"Pathologic findings of Fabry nephropathy: the pivotal role of kidney biopsy","volume":"40","author":"Shin","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.pcad.2025.08.003_bb0440","first-page":"13","article-title":"The Role of Kidney Biopsy in Fabry disease","author":"Capelli","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.pcad.2025.08.003_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00449","article-title":"Signatures of Altered Gene Expression in Dorsal Root Ganglia of a Fabry disease Mouse Model","volume":"10","author":"Kummer","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pcad.2025.08.003_bb0450","doi-asserted-by":"crossref","DOI":"10.23876\/j.krcp.25.066","article-title":"How should kidney injury in Fabry disease be assessed and monitored?","author":"Song","year":"2025","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.pcad.2025.08.003_bb0455","first-page":"13","article-title":"Proton Density of the Dorsal Root Ganglia in Classical Fabry disease: MRI Correlates of Small Fibre Neuropathy","author":"Weiner","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.pcad.2025.08.003_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.107000","article-title":"Impaired plasma membrane calcium ATPase activity and mitochondrial dysfunction contribute to calcium dysregulation in Fabry disease-related painful neuropathy","volume":"213","author":"Formaggio","year":"2025","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108545","article-title":"Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA","volume":"143","author":"Higuchi","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0470","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/WNL.0000000000004396","article-title":"Human dorsal root ganglion in vivo morphometry and perfusion in Fabry painful neuropathy","volume":"89","author":"Godel","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2025.08.003_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180581","article-title":"Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy","volume":"12","author":"Liguori","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb0480","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2025.08.003_bb0485","doi-asserted-by":"crossref","first-page":"fcae095","DOI":"10.1093\/braincomms\/fcae095","article-title":"Small fibre neuropathy in Fabry disease: a human-derived neuronal in vitro disease model and pilot data","volume":"6","author":"Klein","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.pcad.2025.08.003_bb0490","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10384-008-0572-4","article-title":"A case of anterior ischemic optic neuropathy associated with Fabry\u2019s disease","volume":"52","author":"Kumagai","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0495","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/mus.20130","article-title":"Neuropathy and Fabry\u2019s disease","volume":"31","author":"Lacomis","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pcad.2025.08.003_bb0500","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1526-4637.2008.00470.x","article-title":"Detection of a characteristic painful neuropathy in Fabry disease: a pilot study","volume":"9","author":"Maag","year":"2008","journal-title":"Pain Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0505","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/j.pain.0000000000002152","article-title":"Fabry disease pain: patient and preclinical parallels","volume":"162","author":"Burand","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.pcad.2025.08.003_bb0510","doi-asserted-by":"crossref","first-page":"095","DOI":"10.1055\/s-0039-1697072","article-title":"Case Report of Rare Case of Cardiac Variant of Fabry\u2019s Disease in a 2-Year-Old Child","volume":"04","author":"Akidi","year":"2019","journal-title":"Indian Journal of Cardiovascular Disease in Women Wincars"},{"key":"10.1016\/j.pcad.2025.08.003_bb0515","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3344\/kjp.2010.23.3.207","article-title":"Early Diagnosis of Fabry disease in a Patient With Toe Tip Pain","volume":"23","author":"Park","year":"2010","journal-title":"The Korean Journal of Pain"},{"key":"10.1016\/j.pcad.2025.08.003_bb0520","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40268-023-00421-x","article-title":"Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry disease: Preclinical Evaluation","volume":"23","author":"Kuilenburg","year":"2023","journal-title":"Drugs R&D"},{"key":"10.1016\/j.pcad.2025.08.003_bb0525","doi-asserted-by":"crossref","DOI":"10.1177\/09636897231173734","article-title":"<i>In Vivo<\/I> Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells","volume":"32","author":"Nakajima","year":"2023","journal-title":"Cell Transplant"},{"key":"10.1016\/j.pcad.2025.08.003_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.106908","article-title":"Disrupted synaptic gene expression in Fabry disease: Findings from RNA sequencing","volume":"209","author":"Lopez-Valverde","year":"2025","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0535","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/nep.12977","article-title":"Globotriaosylsphingosine Induces Oxidative DNA Damage in Cultured Kidney Cells","volume":"22","author":"Biancini","year":"2017","journal-title":"Nephrology"},{"key":"10.1016\/j.pcad.2025.08.003_bb0540","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5478\/MSL.2015.6.4.116","article-title":"A Fast Determination of Globotriaosylsphingosine in Plasma for Screening Fabry disease Using UPLC-ESI-MS\/MS","volume":"6","author":"Yoon","year":"2015","journal-title":"Mass Spectrometry Letters"},{"key":"10.1016\/j.pcad.2025.08.003_bb0545","first-page":"133","article-title":"Accumulation of \u0391-Synuclein Mediates Podocyte Injury in Fabry Nephropathy","author":"Braun","year":"2023","journal-title":"J Clin Investig"},{"key":"10.1016\/j.pcad.2025.08.003_bb0550","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04475-y","article-title":"Proteomic Analysis Unveils Gb3-Independent Alterations and Mitochondrial Dysfunction in a Gla\u2212\/\u2212 Zebrafish Model of Fabry disease","volume":"21","author":"Elsaid","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0555","first-page":"14","article-title":"Fabry disease and Inflammation: Potential Role of p65 iso5, an Isoform of the NF-kappaB Complex","author":"Biddeci","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0560","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036815","article-title":"Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down-Regulation of Mannose-6-Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy","volume":"14","author":"Frustaci","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.08.003_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158273","article-title":"Inflammation, Oxidative Stress, and Endothelial Dysfunction in the Pathogenesis of Vascular Damage: Unraveling Novel Cardiovascular Risk Factors in Fabry disease","volume":"25","author":"Faro","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0570","doi-asserted-by":"crossref","first-page":"1420067","DOI":"10.3389\/fcvm.2024.1420067","article-title":"Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications","volume":"11","author":"Kurdi","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0575","first-page":"13","article-title":"Inflammation and Exosomes in Fabry disease Pathogenesis","author":"Coelho-Ribeiro","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0580","doi-asserted-by":"crossref","first-page":"1307558","DOI":"10.3389\/fimmu.2024.1307558","article-title":"Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy","volume":"15","author":"Laffer","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0585","first-page":"12","article-title":"Circulating Anti-GB3 Antibody as a Biomarker of Myocardial Inflammation in Patients with Fabry disease Cardiomyopathy","author":"Frustaci","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.949","article-title":"Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy","volume":"10","author":"Fu","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.pcad.2025.08.003_bb0595","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry disease After One Year of Enzyme Replacement Therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb0600","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ymgme.2019.05.009","article-title":"Tumor necrosis factor-alpha links heat and inflammation with Fabry pain","volume":"127","author":"Uceyler","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0605","doi-asserted-by":"crossref","first-page":"1340188","DOI":"10.3389\/fendo.2024.1340188","article-title":"Infertility in Fabry\u2019s Disease: role of hypoxia and inflammation in determining testicular damage","volume":"15","author":"Sansone","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pcad.2025.08.003_bb0610","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00415-017-8392-4","article-title":"Evidence for inflammation in Fabry\u2019s disease? Headache and muscle involvement responding to corticosteroid and methotrexate treatment","volume":"264","author":"Kraemer","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0615","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb0620","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2169\/internalmedicine.49.3724","article-title":"Fabry disease exhibiting recurrent stroke and persistent inflammation","volume":"49","author":"Kikumoto","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0625","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0630","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 Activates Notch1 in Human Podocytes","volume":"24","author":"S\u00e1nchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0635","series-title":"Gehmlich K and Steeds RP","first-page":"13","author":"Thompson","year":"2025"},{"key":"10.1016\/j.pcad.2025.08.003_bb0640","doi-asserted-by":"crossref","first-page":"12252","DOI":"10.3390\/ijms252212252","article-title":"Complement System and Adhesion Molecule Skirmishes in Fabry disease: Insights Into Pathogenesis and Disease Mechanisms","volume":"25","author":"Magnusen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0645","first-page":"3","article-title":"Electrocardiographic Changes and Arrhythmia in Fabry disease","author":"Namdar","year":"2016","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10.1016\/j.pcad.2025.08.003_bb0650","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jelectrocard.2019.12.007","article-title":"Tp-e interval and Tp-e\/QT ratio and their association with left ventricular diastolic dysfunction in Fabry disease without left ventricular hypertrophy","volume":"59","author":"Yenercag","year":"2020","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0655","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000803","article-title":"Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease","volume":"5","author":"Liu","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.pcad.2025.08.003_bb0660","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","article-title":"Systolic and diastolic function assessment in Fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements","volume":"26","author":"Shanks","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2025.08.003_bb0665","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00380-005-0852-6","article-title":"Early diastolic mitral annular velocity and color M-mode flow propagation velocity in the evaluation of left ventricular diastolic function in patients with Fabry disease","volume":"21","author":"Palecek","year":"2006","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pcad.2025.08.003_bb0670","first-page":"12","article-title":"Circulated TGF-beta1 and VEGF-A as Biomarkers for Fabry disease-Associated Cardiomyopathy","author":"Ivanova","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0675","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ehf2.12723","article-title":"Fabry Cardiomyopathy: Gb3-induced Auto-reactive Panmyocarditis Requiring Heart Transplantation","volume":"7","author":"Frustaci","year":"2020","journal-title":"Esc Heart Failure"},{"key":"10.1016\/j.pcad.2025.08.003_bb0680","doi-asserted-by":"crossref","first-page":"15853","DOI":"10.3390\/ijms242115853","article-title":"Interaction of Fabry disease and Diabetes Mellitus: Suboptimal Recruitment of Kidney Protective Factors","volume":"24","author":"S\u00e1nchez-Ni\u00f1o","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0685","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/ehjci\/jeae279","article-title":"Myocardial fibrosis in the posterior myocardium in Fabry disease is associated with global rather than regional longitudinal strain reduction","volume":"26","author":"Maurizi","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb0690","first-page":"13","article-title":"Myocardial Fibrosis Quantification Methods by Cardiovascular Magnetic Resonance Imaging in Patients with Fabry disease","author":"Sokolska","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0695","first-page":"11","article-title":"Prediction of Regulatory SNPs in Putative Minor Genes of the Neuro-Cardiovascular Variant in Fabry Reveals Insights into Autophagy\/Apoptosis and Fibrosis","author":"Ruiz Ramirez","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb0700","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2019.10.010","article-title":"Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis","volume":"129","author":"Rozenfeld","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb0705","first-page":"4027606","article-title":"Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry disease Patients","volume":"2019","author":"Jaurretche","year":"2019","journal-title":"Int J Chronic Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0710","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.case.2017.10.004","article-title":"Progression of Left Ventricular Fibrosis in a Woman with Anderson-Fabry disease: Longitudinal Observations Using Two-Dimensional Speckle-Tracking Echocardiography","volume":"2","author":"Takase","year":"2018","journal-title":"CASE (Phila)"},{"key":"10.1016\/j.pcad.2025.08.003_bb0715","first-page":"7","article-title":"Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry disease Cardiomyopathy","author":"Aguiar","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.08.003_bb0720","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijcard.2017.06.079","article-title":"Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy","volume":"248","author":"Frustaci","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0725","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ijcard.2015.09.045","article-title":"Cardiac Fabry disease with plural mass fibrosis observed in the thickened left ventricular wall","volume":"202","author":"Nishimura","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0730","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kramer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0735","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2261-14-86","article-title":"Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology","volume":"14","author":"Sechi","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pcad.2025.08.003_bb0740","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0745","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/eurheartj\/eht098","article-title":"Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease","volume":"34","author":"Kramer","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb0750","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1161\/CIRCULATIONAHA.105.584292","article-title":"Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease","volume":"113","author":"Hasegawa","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.003_bb0755","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/01.CIR.0000062036.35852.01","article-title":"Images in cardiovascular medicine. Myocardial fibrosis in Fabry disease demonstrated by multislice computed tomography: comparison with biopsy findings","volume":"107","author":"Funabashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.003_bb0760","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.122.001250","article-title":"Mitochondrial microRNAs Are Dysregulated in Patients with Fabry disease","volume":"384","author":"Gambardella","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106074","article-title":"Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease","volume":"26","author":"Gambardella","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.pcad.2025.08.003_bb0770","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143173","article-title":"YAP plays a crucial role in the development of cardiomyopathy in lysosomal storage diseases","volume":"131","author":"Ikeda","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2025.08.003_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108959","article-title":"Metabolic rewiring and autophagy inhibition correct lysosomal storage disease in mucopolysaccharidosis IIIB","volume":"27","author":"Scarcella","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.pcad.2025.08.003_bb0780","first-page":"12","article-title":"Extracellular Vesicles Released by Genetically Modified Macrophages Activate Autophagy and Produce Potent Neuroprotection in Mouse Model of Lysosomal Storage Disorder, Batten Disease","author":"El-Hage","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0785","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1016\/j.ymthe.2022.10.001","article-title":"The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease","volume":"30","author":"Monaco","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb0790","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/hmg\/ddac197","article-title":"Molecular mechanism underlying impaired hepatic autophagy in glycogen storage disease type Ib","volume":"32","author":"Gautam","year":"2023","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0795","first-page":"11","article-title":"Defective Cystinosin, Aberrant Autophagy-Endolysosome Pathways, and Storage Disease: Towards Assembling the Puzzle","author":"Rega","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0800","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jimd.12267","article-title":"Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review","volume":"44","author":"Cho","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0805","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.ymthe.2020.02.005","article-title":"The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease","volume":"28","author":"Monaco","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb0810","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/hmg\/ddaa007","article-title":"The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia","volume":"29","author":"Gautam","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0815","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/hmg\/ddy343","article-title":"Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia","volume":"28","author":"Waskowicz","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0820","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41467-017-02536-7","article-title":"Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney","volume":"9","author":"Festa","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.pcad.2025.08.003_bb0825","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006819","article-title":"Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia","volume":"13","author":"Cho","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005169","article-title":"A missense change in the ATG4D gene links aberrant autophagy to a neurodegenerative vacuolar storage disease","volume":"11","author":"Kyostila","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0835","doi-asserted-by":"crossref","first-page":"158","DOI":"10.15252\/emmm.201404223","article-title":"Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis","volume":"7","author":"Napolitano","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb0840","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nan.12214","article-title":"Impaired autophagy affects acid alpha-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II","volume":"41","author":"Nascimbeni","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0845","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4161\/auto.28623","article-title":"Restarting stalled autophagy a potential therapeutic approach for the lipid storage disorder, Niemann-Pick type C1 disease","volume":"10","author":"Sarkar","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0850","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.celrep.2013.10.042","article-title":"Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease","volume":"5","author":"Sarkar","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb0855","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jhep.2013.05.018","article-title":"Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease","volume":"59","author":"Puls","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0860","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.4161\/auto.21691","article-title":"Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients","volume":"8","author":"Nascimbeni","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0865","doi-asserted-by":"crossref","first-page":"101552","DOI":"10.1016\/j.omtm.2025.101552","article-title":"Effect of disease progression on CSF-directed AAV gene therapy in a large brain animal model of lysosomal storage disease","volume":"33","author":"Hunter","year":"2025","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.pcad.2025.08.003_bb0870","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","article-title":"Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease","volume":"6","author":"Raben","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0875","doi-asserted-by":"crossref","first-page":"C973","DOI":"10.1152\/ajpcell.00527.2009","article-title":"Autophagy in health and disease. 2. Regulation of lipid metabolism and storage by autophagy: pathophysiological implications","volume":"298","author":"Czaja","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0880","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0002-9440(10)61253-9","article-title":"Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease)","volume":"167","author":"Koike","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0885","doi-asserted-by":"crossref","first-page":"20220381","DOI":"10.1098\/rstb.2022.0381","article-title":"Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson\u2019s diseases: insights for drug discovery","volume":"379","author":"Hull","year":"2024","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0890","first-page":"11","article-title":"The Role of the miR-17-92 Cluster in Autophagy and Atherosclerosis Supports Its Link to Lysosomal Storage Diseases","author":"Ortuno-Sahagun","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0895","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jimd.12558","article-title":"Aberrant autophagy in lysosomal storage disorders marked by a lysosomal SNARE protein shortage due to suppression of endocytosis","volume":"45","author":"Tanaka","year":"2022","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100813","article-title":"Enrichment of NPC1-deficient cells with the lipid LBPA stimulates autophagy, improves lysosomal function, and reduces cholesterol storage","volume":"297","author":"Ilnytska","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pcad.2025.08.003_bb0905","first-page":"10","article-title":"Ferroptosis and Its Modulation by Autophagy in Light of the Pathogenesis of Lysosomal Storage Diseases","author":"Pierzynowska","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103166","article-title":"Impaired autophagy: The collateral damage of lysosomal storage disorders","volume":"63","author":"Myerowitz","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pcad.2025.08.003_bb0915","first-page":"76","article-title":"Lysosomal Acid Lipase Drives Adipocyte Cholesterol Homeostasis and Modulates Lipid Storage in Obesity","volume":"70","author":"Gamblin","year":"2021","journal-title":"Independent of Autophagy Diabetes"},{"key":"10.1016\/j.pcad.2025.08.003_bb0920","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/15548627.2020.1840796","article-title":"Ischemia-induced upregulation of autophagy preludes dysfunctional lysosomal storage and associated synaptic impairments in neurons","volume":"17","author":"Zhang","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0925","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnmol.2020.00037","article-title":"Protein Aggregation and Dysfunction of Autophagy-Lysosomal Pathway: A Vicious Cycle in Lysosomal Storage Diseases","volume":"13","author":"Monaco","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.pcad.2025.08.003_bb0930","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/EBC20170055","article-title":"Dysregulation of autophagy as a common mechanism in lysosomal storage diseases","volume":"61","author":"Seranova","year":"2017","journal-title":"Essays Biochem"},{"key":"10.1016\/j.pcad.2025.08.003_bb0935","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1172\/JCI94130","article-title":"mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy","volume":"127","author":"Bartolomeo","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2025.08.003_bb0940","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbalip.2016.01.006","article-title":"Autophagy, lipophagy and lysosomal lipid storage disorders","volume":"1861","author":"Ward","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb0945","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/acel.12409","article-title":"Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages","volume":"15","author":"Aflaki","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.pcad.2025.08.003_bb0950","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/15548627.2015.1046671","article-title":"Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the mouse model of mucopolysaccharidosis III type C","volume":"12","author":"Pshezhetsky","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0955","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.4161\/auto.22184","article-title":"Autophagy in astrocytes: a novel culprit in lysosomal storage disorders","volume":"8","author":"Di Malta","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0960","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0965","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4161\/auto.19920","article-title":"Autophagy contributes to lysosomal storage disorders","volume":"8","author":"Shimada","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.pcad.2025.08.003_bb0970","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-8417-2-4","article-title":"Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI","volume":"2","author":"Tessitore","year":"2009","journal-title":"Pathogenetics"},{"key":"10.1016\/j.pcad.2025.08.003_bb0975","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0076-6879(08)04021-4","article-title":"Monitoring autophagy in lysosomal storage disorders","volume":"453","author":"Raben","year":"2009","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.pcad.2025.08.003_bb0980","article-title":"Kaushik S, Gan L","author":"Khawaja","year":"2025","journal-title":"Castillo PE. Cuervo AM. Chaperone-mediated autophagy regulates neuronal activity by sex-specifically remodeling the synaptic proteome. Nature Cell Biology"},{"key":"10.1016\/j.pcad.2025.08.003_bb0985","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/hmg\/ddm289","article-title":"A block of autophagy in lysosomal storage disorders","volume":"17","author":"Settembre","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb0990","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/cvr\/cvq333","article-title":"Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease","volume":"89","author":"Park","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb0995","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1000","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/ATVBAHA.113.302200","article-title":"Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in Fabry disease","volume":"34","author":"Choi","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1005","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma Lyso-Gb3: A Biomarker for Monitoring Fabry Patients During Enzyme Replacement Therapy","volume":"22","author":"Sakuraba","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1010","doi-asserted-by":"crossref","first-page":"19867","DOI":"10.1038\/s41598-025-03020-9","article-title":"Multimodal dynamic retinal vessel analysis offers new insights in microvascular defects in Fabry\u2019s disease","volume":"15","author":"Assaf","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1015","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jcmg.2022.03.004","article-title":"Coronary Microvascular Dysfunction Is Associated With a Worse Cardiac Phenotype in Patients With Fabry disease","volume":"15","author":"Graziani","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1020","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1177\/1120672120974288","article-title":"Evaluation of the reasons for the microvascular changes in patients with Fabry disease using optic coherence tomography angiography","volume":"31","author":"Dogan","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1025","first-page":"10","article-title":"Evaluation of Cerebral Microvascular Regulatory Mechanisms with Transcranial Doppler in Fabry disease","author":"Castro","year":"2020","journal-title":"Brain Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb1030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009104","article-title":"Massive Coronary Microvascular Dysfunction in Severe Anderson-Fabry disease Cardiomyopathy","volume":"12","author":"Graziani","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fneur.2018.00336","article-title":"A143T Variant Fabry disease May Result in a Phenotype With Multifocal Microvascular Cerebral Involvement at a Young Age","volume":"9","author":"Hauth","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1040","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00330-017-5080-9","article-title":"Rapid volumetric photoacoustic tomographic imaging with a Fabry-Perot ultrasound sensor depicts peripheral arteries and microvascular vasomotor responses to thermal stimuli","volume":"28","author":"Plumb","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1045","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1253\/circj.CJ-16-0873","article-title":"Improvement in Microvascular Ischemia After Enzyme Replacement Therapy in Anderson-Fabry disease - Computed Tomography Myocardial Perfusion Imaging","volume":"81","author":"Yuki","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1050","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/CIRCULATIONAHA.114.012178","article-title":"Microvascular angina as prehypertrophic presentation of Fabry disease cardiomyopathy","volume":"130","author":"Frustaci","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.003_bb1055","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/eurjhf\/hft104","article-title":"Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease","volume":"15","author":"Tomberli","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2025.08.003_bb1060","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.003_bb1065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2025.08.003_bb1070","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","article-title":"Radiological evidence of early cerebral microvascular disease in young children with Fabry disease","volume":"147","author":"Cabrera-Salazar","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.pcad.2025.08.003_bb1075","first-page":"15","article-title":"Differentiation of Infiltrative Cardiomyopathy From Hypertrophic Cardiomyopathy Using High-Sensitivity Cardiac Troponin T: A Case-Control Study","author":"Kubo","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pcad.2025.08.003_bb1080","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-213819","article-title":"Atypical Patterns of Cardiac Involvement in Fabry disease","volume":"2016","author":"Coughlan","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1085","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.124.013352","article-title":"Early Atrial Remodeling Drives Arrhythmia in Fabry disease","volume":"18","author":"Roy","year":"2025","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1090","series-title":"Sweat Gland Biopsy: A Possible Early Diagnostic Tool in the Anderson-Fabry disease","author":"Pistone","year":"2016"},{"key":"10.1016\/j.pcad.2025.08.003_bb1095","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/eurheartjsupp\/suae104","article-title":"Cardiac Involvement in Fabry disease: Recent Advances, Unresolved Issues, and Unmet Needs","volume":"27","author":"Pieroni","year":"2025","journal-title":"European Heart Journal Supplements"},{"key":"10.1016\/j.pcad.2025.08.003_bb1100","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2025.08.003_bb1105","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry\u2019s disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1110","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/echo.14508","article-title":"Echocardiographic Features of Fabry Cardiomyopathy\u2014Comparison With Hypertrophy-matched Sarcomeric Hypertrophic Cardiomyopathy","volume":"36","author":"Militaru","year":"2019","journal-title":"Echocardiography"},{"key":"10.1016\/j.pcad.2025.08.003_bb1115","series-title":"Cardiomyocyte Globotriaosylceramide Accumulation in Adult Male Patients With Fabry disease and IVS4 + 919G>A GLA Mutation Is Progressive With Age and Correlates With Left Ventricular Hypertrophy and Reduced Left Ventricular Ejection Fraction","author":"Chang","year":"2023"},{"key":"10.1016\/j.pcad.2025.08.003_bb1120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term Outcome of Enzyme-replacement Therapy in Advanced <scp>F<\/Scp>abry Disease: Evidence for Disease Progression Towards Serious Complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1751-7133.2009.00050.x","article-title":"Cardiac Manifestations of Fabry\u2019s Disease: A Story of Mother and Son","volume":"15","author":"Moses","year":"2009","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.pcad.2025.08.003_bb1130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13023-024-03412-6","article-title":"Quality of life and unmet needs in patients with Fabry disease: a qualitative study","volume":"19","author":"Morales","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13023-024-03131-y","article-title":"A systematic literature review on the health-related quality of life and economic burden of Fabry disease","volume":"19","author":"Jovanovic","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107692","article-title":"Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study","volume":"140","author":"Winter","year":"2023","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb1145","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000633","article-title":"Gastrointestinal Sensory Neuropathy and Dysmotility in Fabry disease: Presentations and Effect on Patient\u2019s Quality of Life","volume":"14","author":"Bar","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106981","article-title":"Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study","volume":"138","author":"Muntze","year":"2023","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb1155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s41687-022-00525-z","article-title":"Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan","volume":"6","author":"Koto","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.pcad.2025.08.003_bb1160","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/13816810.2022.2132515","article-title":"Visual outcome, ocular findings, and visual quality of life in patients with Fabry disease","volume":"43","author":"Nilsson","year":"2022","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1165","doi-asserted-by":"crossref","first-page":"426","DOI":"10.21037\/cdt-22-215","article-title":"Quality of life in patients with Fabry\u2019s disease: a cross-sectional study of 86 adults","volume":"12","author":"Andonian","year":"2022","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb1170","article-title":"Translation of quality of life scale for pediatric patients with Fabry disease in Japan","volume":"31","author":"Koto","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1180","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.gim.0000223545.63012.5a","article-title":"Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease","volume":"8","author":"Street","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1190","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb1200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1015009210639","article-title":"Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention","volume":"11","author":"Miners","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb1205","first-page":"56","article-title":"Health-related quality of life in Norwegian adults with Fabry disease: Disease severity, pain, fatigue and psychological distress","volume":"62","author":"Pihlstrom","year":"2021","journal-title":"JIMD Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1210","first-page":"9","article-title":"Survey about the Quality of Life of Italian Patients with Fabry disease","author":"Polistena","year":"2021","journal-title":"Diseases"},{"key":"10.1016\/j.pcad.2025.08.003_bb1215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13023-021-02066-y","article-title":"The impact of demographic and clinical characteristics on the trajectories of health-related quality of life among patients with Fabry disease","volume":"16","author":"Sigurdardottir","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1220","article-title":"Depression, sleep disturbances, pain, disability and quality of LIFE in Brazilian Fabry disease patients","volume":"22","author":"Rosa Neto","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1225","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","article-title":"Symptoms and Quality of Life in Patients with Fabry disease: Results from an International Patient Survey","volume":"36","author":"Morand","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb1230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11325-019-01832-4","article-title":"Obstructive sleep apnea and quality of life in Fabry disease: a prospective parallel cohort study","volume":"24","author":"Gaisl","year":"2020","journal-title":"Sleep Breath"},{"key":"10.1016\/j.pcad.2025.08.003_bb1235","first-page":"37","article-title":"The Influence of Patient-Reported Joint Manifestations on Quality of Life in Fabry Patients","volume":"41","author":"Ivleva","year":"2018","journal-title":"JIMD Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1240","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","article-title":"Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study","volume":"41","author":"Arends","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1250","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2369-15-188","article-title":"Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease","volume":"15","author":"Wagner","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1255","first-page":"31","article-title":"Quality of life of brazilian patients with Gaucher disease and Fabry disease","volume":"7","author":"Oliveira","year":"2013","journal-title":"JIMD Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ymgme.2011.07.006","article-title":"Impact of growing up with Fabry disease on achievement of psychosocial milestones and quality of life","volume":"104","author":"Bouwman","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb1265","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1270","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13023-025-03812-2","article-title":"Characterizing pain in patients with Fabry disease: findings from a web-based cross-sectional survey in the US","volume":"20","author":"Wallace","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1275","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1540-8191.2012.01459.x","article-title":"Cardiac Surgery in Patients With Fabry\u2019s Disease: Review of Literature","volume":"27","author":"Fernandez","year":"2012","journal-title":"J Card Surg"},{"key":"10.1016\/j.pcad.2025.08.003_bb1280","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ncn3.148","article-title":"Cardioembolic Stroke in the Cardiac Variant of Fabry disease","volume":"3","author":"Nishimura","year":"2014","journal-title":"Neurol Clin Neurosci"},{"key":"10.1016\/j.pcad.2025.08.003_bb1285","article-title":"Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre","volume":"43","author":"McCarron","year":"2025","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1290","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","article-title":"Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis","volume":"34","author":"Yousef","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1295","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-016-0382-4","article-title":"Myocardial Lipid Content in Fabry disease: A Combined 1h-MR Spectroscopy and MR Imaging Study at 3 Tesla","volume":"16","author":"Petritsch","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pcad.2025.08.003_bb1300","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/ANC.0000000000000569","article-title":"Hunter Syndrome: Is It Time to Make It Part of Newborn Screening?","volume":"18","author":"Joseph","year":"2018","journal-title":"Adv Neonatal Care"},{"key":"10.1016\/j.pcad.2025.08.003_bb1305","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1399-0004.2010.01574.x","article-title":"Female Hunter syndrome caused by a single mutation and familial XCI skewing: implications for other X-linked disorders","volume":"80","author":"Kloska","year":"2011","journal-title":"Clin Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1310","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1315","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.40.4.e38","article-title":"Clinical presentation in female patients with Fabry disease","volume":"40","author":"Guffon","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1320","doi-asserted-by":"crossref","unstructured":"MacDermot KD, Holmes A and Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24 Suppl 2:13-4; discussion 11-2.","DOI":"10.1023\/A:1012447102358"},{"key":"10.1016\/j.pcad.2025.08.003_bb1325","first-page":"81","article-title":"Cardiac transplantation for Fabry\u2019s disease","volume":"14","author":"Cantor","year":"1998","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2261-12-39","article-title":"A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report","volume":"12","author":"Pisani","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pcad.2025.08.003_bb1335","doi-asserted-by":"crossref","first-page":"1536114","DOI":"10.3389\/fcvm.2025.1536114","article-title":"Females with Fabry disease: an expert opinion on diagnosis, clinical management, current challenges and unmet needs","volume":"12","author":"Tuttolomondo","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1340","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.40.8.e103","article-title":"Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers","volume":"40","author":"Morrone","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1345","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08035320600618809","article-title":"Disease manifestations and X inactivation in heterozygous females with Fabry disease","volume":"95","author":"Maier","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2025.08.003_bb1350","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1529-8027.2009.00227.x","article-title":"Autonomic skin responses in females with Fabry disease","volume":"14","author":"Moller","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.pcad.2025.08.003_bb1355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdermsci.2008.04.009","article-title":"Clinical and genetic analysis of Fabry disease: report of six cases including three heterozygous females","volume":"52","author":"Nagasaki","year":"2008","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb1360","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00428-008-0653-2","article-title":"Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy","volume":"453","author":"Valbuena","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pcad.2025.08.003_bb1365","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pcad.2025.08.003_bb1370","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-025-03600-y","article-title":"Impact of enzyme replacement therapy and migalastat on disease progression in females with Fabry disease","volume":"20","author":"Lenders","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1375","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s13023-024-03503-4","article-title":"Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease","volume":"19","author":"Lenders","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1380","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13023-022-02599-w","article-title":"The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants","volume":"18","author":"Sanchez","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1385","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ajmg.a.62728","article-title":"Pitfalls of X-chromosome inactivation testing in females with Fabry disease","volume":"188","author":"Reboun","year":"2022","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pcad.2025.08.003_bb1390","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/cge.13694","article-title":"Diagnostic strategy for females suspected of Fabry disease","volume":"97","author":"Balendran","year":"2020","journal-title":"Clin Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1395","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1651-2227.2008.00649.x","article-title":"Early therapeutic intervention in females with Fabry disease?","volume":"97","author":"Hughes","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.pcad.2025.08.003_bb1400","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 3","key":"10.1016\/j.pcad.2025.08.003_bb1405","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10545-007-0740-6","article-title":"Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease","volume":"31","author":"Kobayashi","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101439","article-title":"Cardiac Involvement in Fabry disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring","volume":"48","author":"Umer","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1415","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ehjci\/jeaf038","article-title":"The role of cardiovascular multimodality imaging in the evaluation of Anderson-Fabry disease: from early diagnosis to therapy monitoring","volume":"26","author":"Cameli","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1420","first-page":"12","article-title":"Fabry disease: More than a Phenocopy of Hypertrophic Cardiomyopathy","author":"Stankowski","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1425","first-page":"23","article-title":"Echocardiography in Anderson-Fabry disease","author":"Lillo","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.47363\/JJCMR\/2022(2)135","article-title":"Correlation Between Transmitral Early and Late Diastolic Velocities Ratio and Ratio of Medial Mitral Annular Early and Late Tissue Doppler Velocities","author":"Maisuradze","year":"2022","journal-title":"Japan Journal of Clinical & Medical Research"},{"key":"10.1016\/j.pcad.2025.08.003_bb1435","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21776\/ub\/hsj.2024.005.02.5","article-title":"Echocardiographic Features in Patient Rheumatic Mitral Stenosis","volume":"5","author":"Dwigustiningrum","year":"2024","journal-title":"Heart Science Journal"},{"key":"10.1016\/j.pcad.2025.08.003_bb1440","series-title":"Cardiomyopathies","author":"Karatasakis","year":"2011"},{"key":"10.1016\/j.pcad.2025.08.003_bb1445","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.echo.2013.08.024","article-title":"Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy","volume":"26","author":"Boyd","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2025.08.003_bb1450","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.hlc.2019.04.017","article-title":"Echocardiography in Infiltrative Cardiomyopathy","volume":"28","author":"Perry","year":"2019","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.pcad.2025.08.003_bb1455","first-page":"11","article-title":"Stress Echocardiography: The Role in Assessing Valvular Heart Diseases","author":"Raissi","year":"2018","journal-title":"Current Cardiovascular Imaging Reports"},{"key":"10.1016\/j.pcad.2025.08.003_bb1460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131891","article-title":"Left atrial structural and functional remodelling in Fabry disease and cardiac amyloidosis: A comparative analysis","volume":"402","author":"Meucci","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131357","article-title":"Left atrial remodeling in hypertrophic cardiomyopathy and Fabry disease: A CMR-based head-to-head comparison and outcome analysis","volume":"393","author":"Moroni","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1470","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00330-022-09183-7","article-title":"Left atrial strain correlates with severity of cardiac involvement in Anderson-Fabry disease","volume":"33","author":"Halfmann","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1475","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12574-020-00508-3","article-title":"Efficacy of Echocardiography for Differential Diagnosis of Left Ventricular Hypertrophy: Special Focus on Speckle-Tracking Longitudinal Strain","volume":"19","author":"Tanaka","year":"2021","journal-title":"Journal of Echocardiography"},{"key":"10.1016\/j.pcad.2025.08.003_bb1480","first-page":"10","article-title":"Fabry Cardiomyopathy: Current Practice and Future Directions","author":"Yim","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb1485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.132967","article-title":"Characteristics of atrial ventricular coupling and left atrial function impairment in early Fabry disease patients using two-dimensional speckle tracking echocardiography","volume":"422","author":"Fan","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1490","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jcu.23612","article-title":"The role of two dimensional speckle tracking echocardiography in determining cardiac prognosis and monitoring enzyme replacement therapy efficacy in patients with Anderson-Fabry disease","volume":"52","author":"Nabati","year":"2024","journal-title":"J Clin Ultrasound"},{"key":"10.1016\/j.pcad.2025.08.003_bb1495","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1093\/eurheartj\/ehaa517","article-title":"Apical sparing on speckle tracking in Morbus Fabry","volume":"41","author":"Suwalski","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1500","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/echo.14592","article-title":"Mechanical dispersion in Fabry disease assessed with speckle tracking echocardiography","volume":"37","author":"Cianciulli","year":"2020","journal-title":"Echocardiography"},{"key":"10.1016\/j.pcad.2025.08.003_bb1505","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/echo.14399","article-title":"Layer-specific longitudinal strain in Anderson-Fabry disease at diagnosis: A speckle tracking echocardiography analysis","volume":"36","author":"Esposito","year":"2019","journal-title":"Echocardiography"},{"issue":"170\u2013179","key":"10.1016\/j.pcad.2025.08.003_bb1510","article-title":"Impaired Left Atrial Function in Fabry disease: A Longitudinal Speckle-Tracking Echocardiography Study","volume":"30","author":"Pichette","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2025.08.003_bb1515","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10554-014-0551-4","article-title":"Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status","volume":"31","author":"Morris","year":"2015","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1520","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/echo.12216","article-title":"Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease","volume":"30","author":"Saccheri","year":"2013","journal-title":"Echocardiography"},{"key":"10.1016\/j.pcad.2025.08.003_bb1525","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.118.034338","article-title":"Fully Automated Echocardiogram Interpretation in Clinical Practice","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.003_bb1530","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2589-7500(20)30267-3","article-title":"Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: a comparison with human test-retest performance","volume":"3","author":"Augusto","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.pcad.2025.08.003_bb1535","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pcad.2025.08.003_bb1540","doi-asserted-by":"crossref","first-page":"15882","DOI":"10.1038\/s41598-024-66247-y","article-title":"Diagnostic accuracy of artificial intelligence in detecting left ventricular hypertrophy by electrocardiograph: a systematic review and meta-analysis","volume":"14","author":"Siranart","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1545","doi-asserted-by":"crossref","first-page":"1440636","DOI":"10.3389\/fcvm.2024.1440636","article-title":"Cardiac involvement in Anderson-Fabry disease. The role of advanced echocardiography","volume":"11","author":"Spinelli","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1550","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.041627","article-title":"Evolution of Cardiac Damage Staged With Echocardiography in Fabry disease","volume":"14","author":"Lillo","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.08.003_bb1555","doi-asserted-by":"crossref","first-page":"ytae660","DOI":"10.1093\/ehjcr\/ytae660","article-title":"Echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation procedure for the treatment of Fabry disease: a case report","volume":"9","author":"Shi","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1560","doi-asserted-by":"crossref","first-page":"1467815","DOI":"10.3389\/fcvm.2024.1467815","article-title":"Role of standard echocardiography in Anderson-Fabry disease","volume":"11","author":"Conte","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1565","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13023-024-03396-3","article-title":"Evaluation of global and regional myocardial work by echocardiography in patients with Fabry disease","volume":"19","author":"Wang","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1570","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2023.08.009","article-title":"Staging of Fabry Cardiomyopathy by Echocardiography: Back to the Roots?","volume":"82","author":"Sunder-Plassmann","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1575","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/ehjci\/jead164","article-title":"Echocardiography in Fabry disease: how many dimensions do we need?","volume":"24","author":"Voigt","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1580","doi-asserted-by":"crossref","first-page":"201","DOI":"10.31083\/j.rcm2306201","article-title":"Echocardiography in Anderson-Fabry disease","volume":"23","author":"Lillo","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1585","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.838200","article-title":"Importance of Echocardiography and Clinical \u201cRed Flags\u201d in Guiding Genetic Screening for Fabry disease","volume":"9","author":"Citro","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1590","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.2020190149","article-title":"Left Ventricular Mass and Wall Thickness Measurements Using Echocardiography and Cardiac MRI in Patients with Fabry disease: Clinical Significance of Discrepant Findings","volume":"2","author":"O\u2019Brien","year":"2020","journal-title":"Radiol Cardiothorac Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1595","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.acvd.2020.04.008","article-title":"The value of electrocardiography and echocardiography in distinguishing Fabry disease from sarcomeric hypertrophic cardiomyopathy","volume":"113","author":"Junqua","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb1600","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/echo.14707","article-title":"Pulse-cancellation echocardiography in Fabry disease diagnosis","volume":"37","author":"Joye","year":"2020","journal-title":"Echocardiography"},{"key":"10.1016\/j.pcad.2025.08.003_bb1605","doi-asserted-by":"crossref","first-page":"1000028","DOI":"10.2340\/20030711-1000028","article-title":"Serial Analysis of Cardiopulmonary Fitness and Echocardiography in Patients with Fabry disease Undergoing Enzyme Replacement Therapy","volume":"3","author":"Tuan","year":"2020","journal-title":"J Rehabil Med Clin Commun"},{"key":"10.1016\/j.pcad.2025.08.003_bb1610","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1475-097X.2008.00851.x","article-title":"Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance","volume":"29","author":"Koskenvuo","year":"2009","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1615","first-page":"1041","article-title":"Comparison of Cardiac Magnetic Resonance Imaging and Echocardiography in Assessment of Left Ventricular Hypertrophy in Fabry disease","volume":"34","author":"Hazari","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1620","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-7120-3-11","article-title":"Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography","volume":"3","author":"Dimitrow","year":"2005","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.pcad.2025.08.003_bb1625","volume":"3","author":"Niemann","year":"2013","journal-title":"Echocardiography in Fabry disease Cardiogenetics"},{"key":"10.1016\/j.pcad.2025.08.003_bb1630","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.3390\/jcm13195953","article-title":"NT-proBNP Reflects Left Ventricular Hypertrophy Rather Than Left Ventricular Dilatation or Systolic Dysfunction in Patients With Fabry disease","volume":"13","author":"Gatterer","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1635","doi-asserted-by":"crossref","first-page":"1000028","DOI":"10.2340\/20030711-1000028","article-title":"Serial Analysis of Cardiopulmonary Fitness and Echocardiography in Patients With Fabry disease Undergoing Enzyme Replacement Therapy","volume":"3","author":"Tuan","year":"2020","journal-title":"Journal of Rehabilitation Medicine \u2013 Clinical Communications"},{"key":"10.1016\/j.pcad.2025.08.003_bb1640","first-page":"14","article-title":"Clinical Efficacy and Real-World Effectiveness of Fabry disease Treatments: A Systematic Literature Review","author":"Jovanovic","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1645","doi-asserted-by":"crossref","first-page":"23","DOI":"10.25259\/JCIS_155_2024","article-title":"Cardiac magnetic resonance imaging in Fabry disease","volume":"15","author":"Chau","year":"2025","journal-title":"J Clin Imaging Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb1650","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/jcecho.jcecho_119_20","article-title":"Regional Strain Pattern and Correlation With Cardiac Magnetic Resonance Imaging in Fabry disease","volume":"31","author":"Kimonis","year":"2021","journal-title":"Journal of Cardiovascular Echography"},{"key":"10.1016\/j.pcad.2025.08.003_bb1655","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jjcc.2019.09.002","article-title":"Clinical Findings of Gadolinium-Enhanced Cardiac Magnetic Resonance in Fabry Patients","volume":"75","author":"Nojiri","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1660","article-title":"Left Ventricular Hemodynamic Forces Changes in Fabry disease: A Cardiac Magnetic Resonance Study","author":"Li","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1665","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/heartjnl-2015-308494","article-title":"Cardiac Involvement in Genotype-Positive Fabry disease Patients Assessed by Cardiovascular MR","volume":"102","author":"Kozor","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2025.08.003_bb1670","doi-asserted-by":"crossref","first-page":"192","DOI":"10.31083\/j.rcm2306192","article-title":"Fabry disease Cardiomyopathy: A Review of the Role of Cardiac Imaging from Diagnosis to Treatment","volume":"23","author":"Fuertes Kenneally","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1675","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","article-title":"Role of Cardiac MRI in Evaluating Patients With Anderson-Fabry disease: Assessing Cardiac Effects of Long-Term Enzyme Replacement Therapy","volume":"117","author":"Messalli","year":"2011","journal-title":"Radiol Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1680","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10554-025-03331-y","article-title":"NASCI case of the month: \u201cpseudo normalization of T1 values in Anderson-Fabry disease\u201d","volume":"41","author":"Sarquiz","year":"2025","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1685","first-page":"12","article-title":"Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM)","author":"Lau","year":"2025","journal-title":"Open Heart"},{"key":"10.1016\/j.pcad.2025.08.003_bb1690","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00392-002-0870-7","article-title":"Fabry disease in patients with hypertrophic cardiomyopathy (HCM)","volume":"91","author":"Beer","year":"2002","journal-title":"Z Kardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1695","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry disease","volume":"12","author":"Perry","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1700","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/00015385.2024.2346873","article-title":"Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis","volume":"79","author":"Paelinck","year":"2024","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1705","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/heartjnl-2020-318271","article-title":"Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy","volume":"108","author":"Vitale","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2025.08.003_bb1710","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101466","article-title":"Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry\u2019s disease","volume":"38","author":"Olivera","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.pcad.2025.08.003_bb1715","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1121","article-title":"Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis","volume":"8","author":"Ugga","year":"2018","journal-title":"Brain Behav"},{"key":"10.1016\/j.pcad.2025.08.003_bb1720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071894","article-title":"Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?","volume":"8","author":"Bottcher","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb1725","first-page":"27","article-title":"Fabry\u2019s disease as a differential diagnosis of MS","volume":"13","author":"Callegaro","year":"2006","journal-title":"Int MS J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1730","doi-asserted-by":"crossref","DOI":"10.1159\/000060198","article-title":"Angiokeratoma and pain, but not Fabry\u2019s disease: considerations for differential diagnosis","volume":"256-9","author":"Ries","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1735","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/milmed\/162.11.773","article-title":"Fabry\u2019s disease presenting as syncope, angiokeratomas, and spoke-like cataracts in a young man: discussion of the differential diagnosis","volume":"162","author":"Menkes","year":"1997","journal-title":"Mil Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1740","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3126\/njh.v16i1.23904","article-title":"Stroke in Young Secondary to Infective Endocarditis Complicating Hypertrophic Cardiomyopathy \u2013 A Case Report","volume":"16","author":"Bhandari","year":"2019","journal-title":"Nepalese Heart Journal"},{"key":"10.1016\/j.pcad.2025.08.003_bb1745","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/jcm11051233","article-title":"Sphingosine-1-Phosphate Levels Are Higher in Male Patients With Non-Classic Fabry disease","volume":"11","author":"Mauhin","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1750","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI118981","volume":"98","author":"Miyamura","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2025.08.003_bb1755","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM197403142901117","article-title":"Letter: Enhancement of enzymatic activity in Fabry\u2019s disease","volume":"290","author":"Christensen","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1760","doi-asserted-by":"crossref","first-page":"ytae375","DOI":"10.1093\/ehjcr\/ytae375","article-title":"The role of genetic testing in diagnosing Fabry\u2019s disease and its overlapping with cardiomyopathies: a case series","volume":"8","author":"Suppah","year":"2024","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1765","first-page":"13","article-title":"The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry disease among At-Risk Family Members of 83 Index Patients","author":"Moiseev","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb1770","first-page":"150","article-title":"Application of Genetic Testing in Unveiling the Diagnosis of Fabry disease in a Patient with Hypertrophic Cardiomyopathy","volume":"74","author":"Gedela","year":"2021","journal-title":"S D Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1775","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1666","article-title":"The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease","volume":"9","author":"Germain","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1780","first-page":"1","article-title":"Female with Fabry disease Unknowingly Donates Affected Kidney to Sister: A Call for Pre-transplant Genetic Testing","volume":"4","author":"Paull","year":"2012","journal-title":"JIMD Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1785","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/eurjhf\/hfq080","article-title":"Screening for Fabry disease using genetic testing","volume":"12","author":"Weidemann","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2025.08.003_bb1790","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.diii.2025.04.005","article-title":"Cardiac MRI in Fabry disease: T1 mapping as a quantitative biomarker for treatment monitoring","volume":"106","author":"Deux","year":"2025","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1795","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.230154","article-title":"Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry disease: A Systematic Review and Meta-Analysis","volume":"6","author":"Figliozzi","year":"2024","journal-title":"Radiol Cardiothorac Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1800","article-title":"Use of T1 mapping in cardiac MRI for the follow-up of Fabry disease in a pediatric population","volume":"38","author":"Werner","year":"2024","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1805","doi-asserted-by":"crossref","first-page":"1075639","DOI":"10.3389\/fcvm.2022.1075639","article-title":"Cardiac MRI in Fabry disease","volume":"9","author":"Umer","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1810","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101476","article-title":"Integrating Cardiac MRI Imaging and Multidisciplinary Clinical Care is Associated With Improved Outcomes in Patients With Fabry disease","volume":"48","author":"Perera","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1815","doi-asserted-by":"crossref","first-page":"20210020","DOI":"10.1259\/bjr.20210020","article-title":"Anderson-Fabry disease: role of traditional and new cardiac MRI techniques","volume":"94","author":"Caredda","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1820","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2214\/AJR.20.23102","article-title":"Increased Spread of Native T1 Values Assessed With MRI as a Marker of Cardiac Involvement in Fabry disease","volume":"216","author":"Karur","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1825","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1148\/radiol.2020200909","article-title":"Predictive Value of Cardiac MRI in Patients with Fabry disease","volume":"296","author":"Tao","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.pcad.2025.08.003_bb1830","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijcard.2019.12.059","article-title":"Prevalence of Anderson-Fabry disease in a cohort with unexplained late gadolinium enhancement on cardiac MRI","volume":"304","author":"Moonen","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1835","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jcmg.2019.09.014","article-title":"Antimalarial-Induced Cardiomyopathy Resembles Fabry disease on Cardiac MRI","volume":"13","author":"Hanneman","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1840","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1148\/radiol.2019192141","article-title":"Grading Cardiac Risk in Fabry disease: Is MRI the Answer?","volume":"294","author":"Zimmerman","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.pcad.2025.08.003_bb1845","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1148\/radiol.2019191385","article-title":"Left Ventricular Hypertrophy and Late Gadolinium Enhancement at Cardiac MRI Are Associated with Adverse Cardiac Events in Fabry disease","volume":"294","author":"Hanneman","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.pcad.2025.08.003_bb1850","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb1855","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","article-title":"Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy","volume":"117","author":"Messalli","year":"2012","journal-title":"Radiol Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1860","doi-asserted-by":"crossref","first-page":"W97","DOI":"10.2214\/AJR.08.1201","article-title":"Delayed-enhanced cardiac MRI for differentiation of Fabry\u2019s disease from symmetric hypertrophic cardiomyopathy","volume":"192","author":"De Cobelli","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1865","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamacardio.2016.5677","article-title":"Assessing the Phenotypic Burden of Preclinical Sarcomeric Hypertrophic Cardiomyopathy-New Assessments to Guide Diagnosis and Management","volume":"2","author":"Tardiff","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1870","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.111.300436","article-title":"Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations","volume":"112","author":"Sequeira","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb1875","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.104.507699","article-title":"Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy","volume":"112","author":"Carniel","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.003_bb1880","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.003_bb1885","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41598-024-52890-y","article-title":"Right heart and left atrial strain to differentiate cardiac amyloidosis and Fabry disease","volume":"14","author":"Mattig","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1890","first-page":"109","article-title":"Amyloid and Anderson-Fabry disease: Can there be a CMR phenotypic overlap?","volume":"31","author":"Alnaimat","year":"2025","journal-title":"J Cardiol Cases"},{"key":"10.1016\/j.pcad.2025.08.003_bb1895","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1900","doi-asserted-by":"crossref","DOI":"10.1186\/s40842-025-00239-3","article-title":"The 2025 AHA\/ACC hypertension guidelines: implications for cardiovascular and renal risk in patients with diabetes","author":"Santulli","year":"2025","journal-title":"Cardiovasc. Diabetol. \u2013 Endocrinol. Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb1905","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.123.001952","article-title":"Achieving a Systolic Blood Pressure Below 130 mmHg Reduces the Incidence of Cardiovascular Events in Hypertensive Patients with Echocardiographic Left Ventricular Hypertrophy","volume":"390","author":"Lembo","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb1910","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ijcard.2016.06.282","article-title":"Apical aneurysm, apical thrombus, ventricular tachycardia and cerebral hemorrhagic infarction in a patient of mid-ventricular non-obstructive hypertrophic cardiomyopathy: A case report","volume":"220","author":"Ma","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1915","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/eurheartj\/ehu146","article-title":"Transapical myectomy for severe mid-ventricular obstructive hypertrophic cardiomyopathy","volume":"35","author":"Ong","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1920","first-page":"475","article-title":"Mid-ventricular hypertrophic obstructive cardiomyopathy presenting with acute myocardial infarction","volume":"34","author":"Sato","year":"2007","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1925","article-title":"Differential diagnosis of hypertrophic cardiomyopathies: typical (subaortic) hypertrophic obstructive cardiomyopathy, atypical (mid-ventricular) hypertrophic obstructive cardiomyopathy and hypertrophic non-obstructive cardiomyopathy","volume":"4 Suppl F:93-104","author":"Kuhn","year":"1983","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1930","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/hrt.39.7.701","article-title":"Mid ventricular obstruction in hypertrophic obstructive cardiomyopathy. New diagnostic and therapeutic challenge","volume":"39","author":"Falicov","year":"1977","journal-title":"Br Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1935","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2020.08.011","article-title":"Cardiac Magnetic Resonance Imaging in Danon Disease Cardiomyopathy","volume":"14","author":"Rigolli","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.003_bb1940","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jacc.2009.11.019","article-title":"Distinct clinical and histopathological presentations of Danon cardiomyopathy in young women","volume":"55","author":"Toib","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb1945","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1253\/circj.CJ-08-0241","article-title":"Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy","volume":"73","author":"Dougu","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.pcad.2025.08.003_bb1950","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pcad.2025.08.003_bb1955","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18330","article-title":"Hypertrophy cardiomyopathy: A case of infantile-onset Pompe disease in cardiac magnetic resonance findings","volume":"9","author":"Zhong","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.pcad.2025.08.003_bb1960","first-page":"12","article-title":"Unusual Evolution of Hypertrophic Cardiomyopathy in Non-Compaction Myocardium in a Pompe Disease Patient","author":"Gragnaniello","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1965","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.cardfail.2011.07.011","article-title":"Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy","volume":"17","author":"Chen","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2025.08.003_bb1970","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2007.09.018","article-title":"Cardiomyopathy in Pompe\u2019s disease","volume":"19","author":"Fayssoil","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb1975","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127048","article-title":"Nano-LC-MS\/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb1980","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/hmg\/ddad073","article-title":"Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease","volume":"32","author":"Nikolaenko","year":"2023","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb1985","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb1990","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb1995","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109110","article-title":"The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review","volume":"145","author":"Ramaswami","year":"2025","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2000","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237358","article-title":"A Rapid and Simple UHPLC-MS\/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3)","volume":"26","author":"Perrone","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.pcad.2025.08.003_bb2005","first-page":"10","article-title":"RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death","author":"Kim","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb2010","first-page":"13","article-title":"NT-proBNP Reflects Left Ventricular Hypertrophy Rather than Left Ventricular Dilatation or Systolic Dysfunction in Patients with Fabry disease","author":"Gatterer","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2011.06.021","article-title":"Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease","volume":"104","author":"Torralba-Cabeza","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157640","article-title":"Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry disease","volume":"11","author":"Tanislav","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb2025","first-page":"5","article-title":"High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry disease","author":"Seydelmann","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.08.003_bb2030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091757","article-title":"Continuous cardiac troponin I release in Fabry disease","volume":"9","author":"Feustel","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb2035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2261-11-6","article-title":"Persistent increase in cardiac troponin I in Fabry disease: a case report","volume":"11","author":"Tanislav","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pcad.2025.08.003_bb2040","doi-asserted-by":"crossref","first-page":"1341590","DOI":"10.3389\/fcvm.2024.1341590","article-title":"Fatigue as hallmark of Fabry disease: role of bioenergetic alterations","volume":"11","author":"Gambardella","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2045","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000545604","article-title":"Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry disease","volume":"11","author":"Yang","year":"2025","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109082","article-title":"Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing","volume":"145","author":"Pan","year":"2025","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2055","article-title":"Using artificial intelligence and promoter-level transcriptome analysis to identify a biomarker as a possible prognostic predictor of cardiac complications in male patients with Fabry disease","volume":"41","author":"Kobayashi","year":"2024","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910329","article-title":"In Silico Modeling of Fabry disease Pathophysiology for the Identification of Early Cellular Damage Biomarker Candidates","volume":"25","author":"Gervas-Arruga","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb2065","doi-asserted-by":"crossref","first-page":"23033","DOI":"10.1038\/s41598-024-73537-y","article-title":"Investigation of serum neurofilament light chain as a biomarker in Fabry disease","volume":"14","author":"Ponleitner","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2070","doi-asserted-by":"crossref","first-page":"fcae155","DOI":"10.1093\/braincomms\/fcae155","article-title":"Dorsal root ganglion magnetic resonance imaging biomarker correlations with pain in Fabry disease","volume":"6","author":"Schindehutte","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.pcad.2025.08.003_bb2075","doi-asserted-by":"crossref","first-page":"1355033","DOI":"10.3389\/fcvm.2024.1355033","article-title":"Overexpression of VEGFalpha as a biomarker of endothelial dysfunction in aortic tissue of alpha-GAL-Tg\/KO mice and its upregulation in the serum of patients with Fabry\u2019s disease","volume":"11","author":"Lund","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13023-023-02759-6","article-title":"Basilar artery diameter as neuroimaging biomarker in Chinese Fabry disease patients","volume":"18","author":"Lam","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2085","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41419-021-04438-5","article-title":"Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson-Fabry disease","volume":"12","author":"Salamon","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5582\/irdr.2021.01115","article-title":"Serum neurofilament light chain is not a useful biomarker of central nervous system involvement in women with Fabry disease","volume":"10","author":"Holub","year":"2021","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb2095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/cimb43010032","article-title":"Plasma Globotriaosylsphingosine and alpha-Galactosidase A Activity as a Combined Screening Biomarker for Fabry disease in a Large Japanese Cohort","volume":"43","author":"Maruyama","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2100","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020356","article-title":"Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry disease","volume":"10","author":"Lo Curto","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pcad.2025.08.003_bb2105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ndt\/gfaa298","article-title":"Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy","volume":"37","author":"Yonishi","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pcad.2025.08.003_bb2110","first-page":"9","article-title":"The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry disease: An Optical Coherence Tomography Angiography Study","author":"Cennamo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2115","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00415-020-10209-7","article-title":"MRI-visible perivascular spaces as an imaging biomarker in Fabry disease","volume":"268","author":"Lyndon","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2120","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1021\/acssensors.0c00348","article-title":"Porous Silicon Fabry-Perot Interferometer for N-Acetyl-beta-d-Glucosaminidase Biomarker Monitoring","volume":"5","author":"Kumar","year":"2020","journal-title":"ACS Sens"},{"key":"10.1016\/j.pcad.2025.08.003_bb2125","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2169\/internalmedicine.3813-19","article-title":"Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry disease","volume":"59","author":"Aoyama","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102379","article-title":"Plasma adiponectin is a potential biomarker for organ involvement in male Fabry disease patients","volume":"80","author":"Hovakimyan","year":"2020","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2135","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral Chaperone Therapy Migalastat for Treating Fabry disease: Enzymatic Response and Serum Biomarker Changes After 1 Year","volume":"105","author":"Muntze","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2140","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ymgme.2018.08.001","article-title":"One-step synthesis of carbon-13-labeled globotriaosylsphingosine (lyso-Gb3), an internal standard for biomarker analysis of Fabry disease","volume":"125","author":"Hong","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2145","first-page":"10","article-title":"A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse","author":"Shin","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pcad.2025.08.003_bb2150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13023-018-0813-7","article-title":"Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial","volume":"13","author":"Schiffmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2155","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1212\/WNL.0000000000005320","article-title":"In search of a putative imaging biomarker for Fabry disease: Go with the flow?","volume":"90","author":"Giese","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2025.08.003_bb2160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10545-017-0127-2","article-title":"Globotriaosylsphingosine (Lyso-Gb(3)) as a biomarker for cardiac variant (N215S) Fabry disease","volume":"41","author":"Alharbi","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2170","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12979-014-0027-3","article-title":"Hypertension in adult Fabry\u2019s disease: is cardiotrophin-1 a diagnostic biomarker?","volume":"11","author":"Marazzi","year":"2014","journal-title":"Immun Ageing"},{"key":"10.1016\/j.pcad.2025.08.003_bb2185","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/ki.2014.126","article-title":"3-Nitrotyrosine as a biomarker for vascular involvement in Fabry disease","volume":"86","author":"Joly","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2025.08.003_bb2190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2025.08.003_bb2195","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2013.09.008","article-title":"Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A)","volume":"426","author":"Liao","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb2200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020534","article-title":"A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy","volume":"6","author":"Kistler","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb2205","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"399","author":"Togawa","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pcad.2025.08.003_bb2210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2215","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2009.04.009","article-title":"Fabry disease urinary globotriaosylceramide\/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months","volume":"97","author":"Barr","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2220","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archderm.141.7.904-b","article-title":"Fabry disease: angiokeratoma, biomarker, and the effect of enzyme replacement therapy on kidney function","volume":"141","author":"Ries","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2025.08.003_bb2230","article-title":"Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy","volume":"43","author":"Ramaswami","year":"2025","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2235","doi-asserted-by":"crossref","first-page":"1415547","DOI":"10.3389\/fcvm.2024.1415547","article-title":"A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta","volume":"11","author":"Oudit","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108561","article-title":"Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey","volume":"143","author":"Nowak","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2245","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/DDDT.S365885","article-title":"Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry disease: Insights from Real-World Data","volume":"18","author":"Feriozzi","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-024-03049-5","article-title":"Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study","volume":"19","author":"Mignani","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2255","doi-asserted-by":"crossref","unstructured":"Shima H, Tsukimura T, Shiga T, Togawa T, Sakuraba H, Doi T, Ikeda Y, Okamoto T, Yoshikawa Y, Kimura T, Iwase T, Inoue T, Tashiro M, Okada K and Minakuchi J. Effects of switching from agalsidase-alpha to agalsidase-beta on biomarkers, renal and cardiac parameters, and disease severity in Fabry disease forming neutralizing antidrug antibodies: a case report. CEN Case Rep 2024;13:290-296.","DOI":"10.1007\/s13730-023-00843-1"},{"key":"10.1016\/j.pcad.2025.08.003_bb2260","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmg-2023-109445","article-title":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study","volume":"61","author":"Wallace","year":"2024","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2265","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cge.14266","article-title":"New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage","volume":"103","author":"Riccio","year":"2023","journal-title":"Clin Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2270","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030345","article-title":"A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease","volume":"101","author":"Hwang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2275","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028830","article-title":"Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-beta and carbamazepine: A case report","volume":"101","author":"Kanai","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2280","first-page":"19","article-title":"Fabry App: The Value of a Portable Technology in Recording Day-to-Day Patient Monitored Information in Patients With Fabry disease","author":"D\u2019Amore","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2285","article-title":"New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review","volume":"1","author":"Riccio","year":"2023","journal-title":"Genet Med Open"},{"key":"10.1016\/j.pcad.2025.08.003_bb2290","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2025.08.003_bb2295","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2021.07.006","article-title":"Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing","volume":"134","author":"Domm","year":"2021","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2300","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13023-025-03705-4","article-title":"Current status of the immunogenicity of enzyme replacement therapy in Fabry disease","volume":"20","author":"Gomez-Cerezo","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2305","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/ijms22031331","article-title":"The Cardiovascular Phenotype in Fabry disease: New Findings in the Research Field","volume":"22","author":"Sorriento","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb2310","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: The Current Treatment Landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.pcad.2025.08.003_bb2315","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating Fabry disease: real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2320","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2325","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00428-008-0586-9","article-title":"Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients","volume":"452","author":"Keslova-Veselikova","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pcad.2025.08.003_bb2330","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2023.07.026","article-title":"Prognostic Implications of the Extent of Cardiac Damage in Patients With Fabry disease","volume":"82","author":"Meucci","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2335","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.carpath.2009.05.003","article-title":"A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy","volume":"19","author":"Sheppard","year":"2010","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2340","first-page":"11","article-title":"Divergent Impact of Enzyme Replacement Therapy on Human Cardiomyocytes and Enterocytes Affected by Fabry disease: Correlation with Mannose-6-phosphate Receptor Expression","author":"Frustaci","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2345","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/eurheartj\/ehae148","article-title":"Anderson-Fabry disease management: role of the cardiologist","volume":"45","author":"Pieroni","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.003_bb2350","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ymgme.2006.01.010","article-title":"Lysosomal storage diseases: natural history and ethical and economic aspects","volume":"88","author":"Beutler","year":"2006","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116024","article-title":"Inflammatory and Cardiovascular Biomarkers to Monitor Fabry disease Progression","volume":"25","author":"Alonso-Nunez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb2360","doi-asserted-by":"crossref","first-page":"181","DOI":"10.31083\/j.rcm.2020.02.65","article-title":"Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction","volume":"21","author":"Madan","year":"2020","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2365","article-title":"Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement Therapy","volume":"7","author":"Morimoto","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2370","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009052","article-title":"Immune-Mediated Myocarditis in Fabry disease Cardiomyopathy","volume":"7","author":"Frustaci","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.08.003_bb2375","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and Investigational Therapeutics for Fabry disease","volume":"5","author":"Felis","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2380","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110779","article-title":"Therapeutic advances in Fabry disease: The future awaits","volume":"131","author":"Kant","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pcad.2025.08.003_bb2385","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2390","first-page":"63","article-title":"The heart in Anderson-Fabry disease","volume":"34","author":"Sestito","year":"2020","journal-title":"J Biol Regul"},{"key":"10.1016\/j.pcad.2025.08.003_bb2395","doi-asserted-by":"crossref","first-page":"1266082","DOI":"10.3389\/fimmu.2023.1266082","article-title":"Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease","volume":"14","author":"Lenders","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2400","first-page":"657","article-title":"Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities","volume":"38","author":"Beraza-Millor","year":"2024","journal-title":"Challenges and Delivery Systems BioDrugs"},{"key":"10.1016\/j.pcad.2025.08.003_bb2405","doi-asserted-by":"crossref","DOI":"10.1136\/jmg-2024-110596","article-title":"Long-term efficacy of migalastat in females with Fabry disease","author":"Kallish","year":"2025","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2410","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0813-7","article-title":"Migalastat Improves Diarrhea in Patients With Fabry disease: Clinical-Biomarker Correlations From the Phase 3 FACETS Trial","volume":"13","author":"Schiffmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2415","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/jimd.12773","article-title":"Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis","volume":"47","author":"Pisani","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109102","article-title":"Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension","volume":"145","author":"Ramaswami","year":"2025","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2425","article-title":"Pathogenicity of novel GLA gene missense mutations in Fabry disease and the therapeutic impact of migalastat","author":"Guo","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb2430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314030","article-title":"Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment","volume":"19","author":"Johnson","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb2435","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12771","article-title":"Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry","volume":"48","author":"Hughes","year":"2025","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2440","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119843","article-title":"Fabry disease Enzyme Enhancement on migalastat Study: FEES","volume":"561","author":"Kugan","year":"2024","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb2445","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/14656566.2024.2354466","article-title":"A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry\u2019s Disease","volume":"25","author":"Majid","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pcad.2025.08.003_bb2450","first-page":"9293896","article-title":"Baseline Characteristics of Fabry disease \u201cAmenable\u201d Migalastat Patients in Argentinian Cohort","volume":"2024","author":"Jaurretche","year":"2024","journal-title":"Glob Health Epidemiol Genom"},{"key":"10.1016\/j.pcad.2025.08.003_bb2455","doi-asserted-by":"crossref","first-page":"1223635","DOI":"10.3389\/fcvm.2023.1223635","article-title":"Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease","volume":"10","author":"Pogoda","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2460","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.4155\/bio-2023-0160","article-title":"Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy","volume":"15","author":"Auray-Blais","year":"2023","journal-title":"Bioanalysis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2465","doi-asserted-by":"crossref","first-page":"1220637","DOI":"10.3389\/fmed.2023.1220637","article-title":"Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study","volume":"10","author":"Bichet","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2470","first-page":"13","article-title":"Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry disease","author":"Gatterer","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2475","article-title":"Medication adherence in Fabry patients treated with migalastat: Real world experience","volume":"35","author":"Riccio","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2480","first-page":"11","article-title":"Fabry disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?","author":"Perretta","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2485","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fca-2022-0080","article-title":"Challenges in Fabry disease: the combination of two individually amenable GLA variants may be nonamenable to migalastat","volume":"19","author":"Fernandes","year":"2023","journal-title":"Future Cardiol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2490","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg-2022-108669","article-title":"Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes","volume":"60","author":"Hughes","year":"2023","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2495","first-page":"13","article-title":"Biomarkers for Monitoring Renal Damage Due to Fabry disease in Patients Treated with Migalastat: A Review for Nephrologists","author":"Jaurretche","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2500","first-page":"14","article-title":"Migalastat Treatment in a Kidney-Transplanted Patient with Fabry disease and N215S Mutation: The First Case Report","author":"Di Stefano","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2505","article-title":"Long-term follow-up of renal function in patients treated with migalastat for Fabry disease","volume":"28","author":"Bichet","year":"2021","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2510","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Feldt-Rasmussen","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2515","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.pcad.2025.08.003_bb2520","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtm.2020.08.012","article-title":"In Vitro and In Vivo Amenability to Migalastat in Fabry disease","volume":"19","author":"Lenders","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.pcad.2025.08.003_bb2525","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2530","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2535","first-page":"1030259","article-title":"Pregnancy Outcome after Exposure to Migalastat for Fabry disease: A Clinical Report","volume":"2019","author":"Haninger-Vacariu","year":"2019","journal-title":"Case Rep Obstet Gynecol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2540","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2545","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cpt.1536","article-title":"Oral Chaperone Therapy Migalastat for the Treatment of Fabry disease: Potentials and Pitfalls of Real-World Data","volume":"106","author":"Korver","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2550","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ymgme.2019.04.005","article-title":"Inter-assay variability influences migalastat amenability assessments among Fabry disease variants","volume":"127","author":"Oommen","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2555","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: A Review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pcad.2025.08.003_bb2560","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/jmedgenet-2017-104826","article-title":"Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment","volume":"54","author":"Mauer","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb2570","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2575","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2580","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2585","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ajmg.a.61105","article-title":"Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study","volume":"179","author":"Hughes","year":"2019","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pcad.2025.08.003_bb2590","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active alpha-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase","volume":"10","author":"Warnock","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2025.08.003_bb2600","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects","volume":"109","author":"Giugliani","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2605","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13023-020-01582-7","article-title":"The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects","volume":"15","author":"Mueller","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2610","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00228-019-02808-9","article-title":"Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects","volume":"76","author":"Boof","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2615","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","article-title":"Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types","volume":"27","author":"Welford","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2620","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry disease on Enzyme Replacement","volume":"103","author":"Guerard","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2625","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jcph.944","article-title":"Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment","volume":"57","author":"Guerard","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","article-title":"Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects","volume":"12","author":"Guerard","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2635","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s12325-024-02881-2","article-title":"Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP)","volume":"41","author":"Schiffmann","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2640","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1474-4422(23)00455-6","article-title":"Venglustat in GBA1-related Parkinson\u2019s disease","volume":"23","author":"Zimran","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2645","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","article-title":"Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Giladi","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2650","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40261-023-01275-6","article-title":"Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers","volume":"43","author":"Li","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pcad.2025.08.003_bb2655","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/mds.29398","article-title":"Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein","volume":"38","author":"Schidlitzki","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.pcad.2025.08.003_bb2660","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1021\/acs.jmedchem.2c01854","article-title":"Structure-Activity Relationship Studies of Venglustat on NTMT1 Inhibition","volume":"66","author":"Deng","year":"2023","journal-title":"J Med Chem"},{"issue":"517\u2013527","key":"10.1016\/j.pcad.2025.08.003_bb2665","article-title":"Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2\/3 Randomized Clinical Trial","volume":"81","author":"Gansevoort","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2675","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/awac379","article-title":"Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial","volume":"146","author":"Schiffmann","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.pcad.2025.08.003_bb2680","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1021\/acs.jmedchem.2c01050","article-title":"Venglustat Inhibits Protein N-Terminal Methyltransferase 1 in a Substrate-Competitive Manner","volume":"65","author":"Dong","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.pcad.2025.08.003_bb2685","first-page":"557","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson\u2019s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded","volume":"12","author":"Peterschmitt","year":"2022","journal-title":"Placebo-Controlled MOVES-PD Trial J Parkinsons Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2690","doi-asserted-by":"crossref","first-page":"20945","DOI":"10.1038\/s41598-021-00404-5","article-title":"Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model","volume":"11","author":"Viel","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2695","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.pcad.2025.08.003_bb2700","doi-asserted-by":"crossref","first-page":"1535099","DOI":"10.3389\/fmed.2025.1535099","article-title":"Eliglustat and cardiac comorbidities in Gaucher disease: a pharmacogenomic approach to safety and efficacy","volume":"12","author":"Ain","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2705","doi-asserted-by":"crossref","first-page":"1543136","DOI":"10.3389\/fped.2025.1543136","article-title":"Eliglustat substrate reduction therapy in children with Gaucher disease type 1","volume":"13","author":"Ain","year":"2025","journal-title":"Front Pediatr"},{"key":"10.1016\/j.pcad.2025.08.003_bb2710","first-page":"11","article-title":"Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy","author":"Istaiti","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2715","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12881-017-0403-x","article-title":"Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy","volume":"18","author":"Kim","year":"2017","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2720","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pcad.2025.08.003_bb2725","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2730","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2735","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2025.08.003_bb2740","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/17446651.2013.846213","article-title":"Eliglustat tartrate, a prototypic glucosylceramide synthase inhibitor","volume":"8","author":"Shayman","year":"2013","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2745","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","article-title":"Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers","volume":"51","author":"Peterschmitt","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2750","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pcad.2025.08.003_bb2755","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pcad.2025.08.003_bb2760","doi-asserted-by":"crossref","first-page":"1025740","DOI":"10.3389\/fphar.2022.1025740","article-title":"Fabry disease: Mechanism and therapeutics strategies","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2765","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2770","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11886-024-02053-2","article-title":"Arrhythmogenesis in Fabry disease","volume":"26","author":"Roy","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2775","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-021-02133-4","article-title":"Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy","volume":"17","author":"Vijapurapu","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2780","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70073","article-title":"Lentivirus-mediated gene therapy for Fabry disease: 5-year End-of-Study results from the Canadian FACTs trial","volume":"15","author":"Khan","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2785","first-page":"13","article-title":"Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy","author":"Ruangsiriluk","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.pcad.2025.08.003_bb2790","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101375","article-title":"Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease","volume":"32","author":"Liefhebber","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.pcad.2025.08.003_bb2795","article-title":"Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [(18)F]AGAL","author":"Kaittanis","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2800","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1089\/hum.2023.222","article-title":"Developing Gene Therapy for Mitigating Multisystemic Pathology in Fabry disease: Proof of Concept in an Aggravated Mouse Model","volume":"35","author":"Boukharov","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108494","article-title":"Usefulness of antibody-drug conjugate as preconditioning for hematopoietic stem cell-targeted gene therapy in wild-type and Fabry disease mouse models","volume":"142","author":"Ogata","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2025.08.003_bb2810","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13023-023-02894-0","article-title":"Systematic gene therapy derived from an investigative study of AAV2\/8 vector gene therapy for Fabry disease","volume":"18","author":"Deng","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2815","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omtm.2023.01.003","article-title":"Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease","volume":"28","author":"Saleh","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.pcad.2025.08.003_bb2820","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2825","first-page":"12","article-title":"Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry disease","author":"Rodriguez-Castejon","year":"2022","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.pcad.2025.08.003_bb2830","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pcad.2025.08.003_bb2835","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 Gene Therapy in a Murine Model of Fabry disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.pcad.2025.08.003_bb2840","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030956","article-title":"Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry disease","volume":"21","author":"Lukas","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pcad.2025.08.003_bb2845","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1566523218666180404161315","article-title":"Genetics and Gene Therapy of Anderson-Fabry disease","volume":"18","author":"Simonetta","year":"2018","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2850","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40259-013-0032-7","article-title":"Gene therapy for Fabry disease: a review of the literature","volume":"27","author":"Ruiz de Garibay","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.pcad.2025.08.003_bb2855","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/DDDT.S36131","article-title":"Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy","volume":"6","author":"Ruiz de Garibay","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pcad.2025.08.003_bb2860","doi-asserted-by":"crossref","first-page":"13777","DOI":"10.1073\/pnas.222221899","article-title":"Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer","volume":"99","author":"Takahashi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pcad.2025.08.003_bb2865","doi-asserted-by":"crossref","unstructured":"Siatskas C and Medin JA. Gene therapy for Fabry disease. J Inherit Metab Dis 2001;24 Suppl 2:25-41.","DOI":"10.1023\/A:1012455421014"},{"key":"10.1016\/j.pcad.2025.08.003_bb2870","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.061020598","article-title":"Preselective gene therapy for Fabry disease","volume":"98","author":"Qin","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pcad.2025.08.003_bb2875","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40259-025-00723-3","article-title":"Progress and Challenges in the Treatment of Fabry disease","volume":"39","author":"Lenders","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.pcad.2025.08.003_bb2880","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trsl.2023.02.005","article-title":"CRISPR\/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model","volume":"258","author":"Cui","year":"2023","journal-title":"Transl Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb2885","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118549","article-title":"CRISPR\/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a Fabry disease vasculopathy model derived from human induced pluripotent stem cells","volume":"397","author":"Shin","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2025.08.003_bb2890","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/hmg\/ddv070","article-title":"Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice","volume":"24","author":"Shen","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2895","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.pcad.2025.08.003_bb2900","first-page":"7","article-title":"Characterization of small fiber pathology in a mouse model of Fabry disease","author":"Hofmann","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.pcad.2025.08.003_bb2905","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.ASN.0000043901.45141.D4","article-title":"Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis","volume":"14","author":"Eitzman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2910","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1681\/ASN.2008111190","article-title":"Decreased nitric oxide bioavailability in a mouse model of Fabry disease","volume":"20","author":"Shu","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2915","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1096\/fj.201800771R","article-title":"alpha-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease","volume":"33","author":"Miller","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.pcad.2025.08.003_bb2920","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.pcad.2025.08.003_bb2925","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1194\/jlr.M100423-JLR200","article-title":"Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseases","volume":"43","author":"Asfaw","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2025.08.003_bb2930","first-page":"11","article-title":"Fabry disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions","author":"Kok","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.pcad.2025.08.003_bb2935","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pcad.2025.08.003_bb2940","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jb\/mvq125","article-title":"Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease","volume":"149","author":"Shiozuka","year":"2011","journal-title":"J Biochem"},{"key":"10.1016\/j.pcad.2025.08.003_bb2945","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"Taguchi","year":"2013","journal-title":"Biochem J"},{"key":"10.1016\/j.pcad.2025.08.003_bb2950","article-title":"Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease","volume":"34","author":"Taguchi","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.pcad.2025.08.003_bb2955","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304415","article-title":"Cardiac manifestations of Fabry disease in G3Stg\/GlaKO and GlaKO mouse models-Translation to Fabry disease patients","volume":"19","author":"Kugadas","year":"2024","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.pcad.2025.08.003_bb2960","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/idoj.IDOJ_136_19","article-title":"Angiokeratoma Corporis Diffusum: An Uncommon Case with Suspected Anderson Fabry Disease","volume":"11","author":"Vadher","year":"2020","journal-title":"Indian Dermatol Online J"},{"issue":"6","key":"10.1016\/j.pcad.2025.08.003_bb2965","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/ijd.14330","article-title":"Angiokeratomas, not everything is Fabry disease","volume":"58","author":"Cuestas","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2970","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0002-9343(61)90037-7","article-title":"Angiokeratoma corporis diffusum universale (Fabry). Presenting as suspected myocardial infarction and pulmonary infarcts","volume":"31","author":"Parkinson","year":"1961","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2975","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry\u2019s Disease: Classification as a Sphingolipidosis and Partial Characterization of a Novel Glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pcad.2025.08.003_bb2980","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease","volume":"276","author":"Brady","year":"1967","journal-title":"Ceramidetrihexosidase deficiency N Engl J Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb2985","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/jid.1965.22","article-title":"Angiokeratoma Corporis Diffusum (Fabry). Histochemical and Electron Microscopic Studies of the Skin","volume":"44","author":"Hashimoto","year":"1965","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pcad.2025.08.003_bb2990","first-page":"325","article-title":"The Genetics of Angiokeratoma Corporis Diffusum (Fabry\u2019s Disease) and Its Linkage Relations with the Xg Locus","volume":"17","author":"Opitz","year":"1965","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pcad.2025.08.003_bb2995","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry\u2019s disease","volume":"289","author":"Brady","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.08.003_bb3000","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1073\/pnas.82.21.7364","article-title":"Fabry disease: isolation of a cDNA clone encoding human alpha-galactosidase A","volume":"82","author":"Calhoun","year":"1985","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:32:11Z","timestamp":1772854331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062025001148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":600,"alternative-id":["S0033062025001148"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.08.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease cardiomyopathy: A state-of-the-art review","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}